Which should be given first, DPP-4 inhibitor or SGLT2 inhibitor, in combination therapy of these two anti-diabetic drugs?

Which should be given first, DPP-4 inhibitor or SGLT2 inhibitor, in combination therapy of these two anti-diabetic drugs? - Which should be given first, DPP-4 inhibitor or SGLT2 inhibitor, in combination therapy of these two anti-diabetic drugs?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038377

Enrollment

Registered

2019-10-26

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

First, linagliptin 5mg is administered for 3 months. Then, add canagliflozin 100mg and administer 2 drugs in combination for 3 months. First, canagliflozin 100mg is administered for 3 months. Then, ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)type 2 diabetes who have inadequate glycemic control (HbA1c more than 7%) under medical treatment by dieting and exercise cure and/or drug treatment 2)patients who have no history of cardiovascular disease 3)no treatment or treatment with stable doses of antihypertensive agents for at least 3 months prior to randomization. 4)no treatment or treatment with stable doses of antiplatelet agents for at least 3 months prior to randomization. 5)patients who give a written informed.

Exclusion criteria

Exclusion criteria: 1)type 1 diabetes 2)patients with severe renal dysfunction (eGFR < 30 ml/min/1.73m2) 3)patients with liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 4)a pregnant woman and/or a woman under breast-feeding 5)patients who have diabetic proliferative retinopathy. 6)patients who have an anamnesis of hypersensitivity to the ingredient of a trial drugs. 7)patients who reciving GLP-1 recepter agonist. 8)patients who thought to be inappropriate to enter this study for some medical reasons by physician's judgments.

Design outcomes

Primary

Measure	Time frame
Change from baseline in HbA1c (after 6 months)	—

Secondary

Measure	Time frame
Hemoglobin, hematocrit, erythropoietin, AST, ALT, gamma GTP, Cre, eGFR, Na, K, Cl, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, RLP cholesterol, uric acid, BNP, cystatin C, CRP, hydroxybutyric acid, glucagon, KIM1, LFABP, 25(OD)VitD, leptin , IL-6, ApoB48, Treg, Th17, HMW adiponectin, FGF21, folic acid ,urinary glucose, urinary protein, urinary keton, urinary albumin, visceral fat area, BMI, blood-pressure, pulse, rate, DPP4 concentration and DPP4 activity. (3 months and 6 months after treatment)	—

Measure

Time frame

Hemoglobin, hematocrit, erythropoietin, AST, ALT, gamma GTP, Cre, eGFR, Na, K, Cl, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, RLP cholesterol, uric acid, BNP, cystatin C, CRP, hydroxybutyric acid, glucagon, KIM1, LFABP, 25(OD)VitD, leptin , IL-6, ApoB48, Treg, Th17, HMW adiponectin, FGF21, folic acid ,urinary glucose, urinary protein, urinary keton, urinary albumin, visceral fat area, BMI, blood-pressure, pulse, rate, DPP4 concentration and DPP4 activity. (3 months and 6 months after treatment)

—

Countries

Japan

Contacts

Public ContactTOSHIE IIJIMA

Dokkyo Medical University Department of Endocrinology and Metabolism

toshie@dokkyomed.ac.jp0282-87-2150

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026